Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX23
|
| gptkbp:brand |
Truseltiq
|
| gptkbp:CASNumber |
872511-34-7
|
| gptkbp:chemicalFormula |
C26H31Cl2N7O3
|
| gptkbp:developer |
Helsinn Healthcare
QED Therapeutics |
| https://www.w3.org/2000/01/rdf-schema#label |
infigratinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:molecularWeight |
563.48 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:palmar-plantar_erythrodysesthesia
fatigue alopecia dry mouth hyperphosphatemia nail toxicity stomatitis |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:FGFR2 |
| gptkbp:usedFor |
gptkb:urothelial_carcinoma
cholangiocarcinoma |
| gptkbp:bfsParent |
gptkb:FGFR1
|
| gptkbp:bfsLayer |
6
|